522 related articles for article (PubMed ID: 15571272)
1. Management of hyperuricemia with rasburicase review.
de Bont JM; Pieters R
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1431-40. PubMed ID: 15571272
[TBL] [Abstract][Full Text] [Related]
2. Prevention and treatment of hyperuricemia in hematological malignancies.
Cairo MS
Clin Lymphoma; 2002 Dec; 3 Suppl 1():S26-31. PubMed ID: 12521386
[TBL] [Abstract][Full Text] [Related]
3. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.
Navolanic PM; Pui CH; Larson RA; Bishop MR; Pearce TE; Cairo MS; Goldman SC; Jeha SC; Shanholtz CB; Leonard JP; McCubrey JA
Leukemia; 2003 Mar; 17(3):499-514. PubMed ID: 12646938
[TBL] [Abstract][Full Text] [Related]
4. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
Cheuk DK; Chiang AK; Chan GC; Ha SY
Cochrane Database Syst Rev; 2014 Aug; (8):CD006945. PubMed ID: 25121561
[TBL] [Abstract][Full Text] [Related]
5. Managing malignancy-associated hyperuricemia with rasburicase.
Cheson BD; Dutcher BS
J Support Oncol; 2005; 3(2):117-24. PubMed ID: 15796443
[TBL] [Abstract][Full Text] [Related]
6. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
Cammalleri L; Malaguarnera M
Int J Med Sci; 2007 Mar; 4(2):83-93. PubMed ID: 17396159
[TBL] [Abstract][Full Text] [Related]
7. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
Cheuk DK; Chiang AK; Chan GC; Ha SY
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD006945. PubMed ID: 28272834
[TBL] [Abstract][Full Text] [Related]
8. Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer.
Cheuk DK; Chiang AK; Chan GC; Ha SY
Cochrane Database Syst Rev; 2010 Jun; (6):CD006945. PubMed ID: 20556770
[TBL] [Abstract][Full Text] [Related]
9. Rasburicase in cancer-related hyperuricemia.
Rodriguez M; Campara M; Haaf C
Drugs Today (Barc); 2011 Aug; 47(8):591-603. PubMed ID: 21850282
[TBL] [Abstract][Full Text] [Related]
10. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
Goldman SC; Holcenberg JS; Finklestein JZ; Hutchinson R; Kreissman S; Johnson FL; Tou C; Harvey E; Morris E; Cairo MS
Blood; 2001 May; 97(10):2998-3003. PubMed ID: 11342423
[TBL] [Abstract][Full Text] [Related]
11. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
Kennedy LD; Ajiboye VO
J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
[TBL] [Abstract][Full Text] [Related]
12. Rasburicase for the treatment of tumor lysis in hematological malignancies.
Malaguarnera G; Giordano M; Malaguarnera M
Expert Rev Hematol; 2012 Feb; 5(1):27-38. PubMed ID: 22272702
[TBL] [Abstract][Full Text] [Related]
13. Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome.
Jeha S; Pui CH
Contrib Nephrol; 2005; 147():69-79. PubMed ID: 15604607
[TBL] [Abstract][Full Text] [Related]
14. [Rasburicase (Fasturtec)].
Vogt B; Gugger M; Frey FJ
Ther Umsch; 2004 Sep; 61(9):579-82. PubMed ID: 15493120
[TBL] [Abstract][Full Text] [Related]
15. Rasburicase for the treatment and prevention of hyperuricemia.
Yim BT; Sims-McCallum RP; Chong PH
Ann Pharmacother; 2003; 37(7-8):1047-54. PubMed ID: 12841818
[TBL] [Abstract][Full Text] [Related]
16. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
Cortes J; Moore JO; Maziarz RT; Wetzler M; Craig M; Matous J; Luger S; Dey BR; Schiller GJ; Pham D; Abboud CN; Krishnamurthy M; Brown A; Laadem A; Seiter K
J Clin Oncol; 2010 Sep; 28(27):4207-13. PubMed ID: 20713865
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: an Indian experience.
Digumarti R; Sinha S; Nirni SS; Patil SG; Pedapenki RM
Indian J Cancer; 2014; 51(2):180-3. PubMed ID: 25104205
[TBL] [Abstract][Full Text] [Related]
18. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies.
Pui CH; Relling MV; Lascombes F; Harrison PL; Struxiano A; Mondesir JM; Ribeiro RC; Sandlund JT; Rivera GK; Evans WE; Mahmoud HH
Leukemia; 1997 Nov; 11(11):1813-6. PubMed ID: 9369411
[TBL] [Abstract][Full Text] [Related]
19. Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies.
Goldman SC
Expert Rev Anticancer Ther; 2003 Aug; 3(4):429-33. PubMed ID: 12934655
[TBL] [Abstract][Full Text] [Related]
20. Clarifying the role of rasburicase in tumor lysis syndrome.
Sood AR; Burry LD; Cheng DK
Pharmacotherapy; 2007 Jan; 27(1):111-21. PubMed ID: 17192165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]